What would be the optimal adjuvant strategy in addition to post-op RT for someone with HPV+ G2 squamous carcinoma of the bladder after radical cystectomy with node negative locally advanced disease ulcerating through the vagina and involving the cervix?

Community
Company
News
Contact Us
Sign in

Topics: Genitourinary Cancers • Bladder Cancer • Medical Oncology

Related Questions

Given results of BCON trial, do you add carbogen and nicotinamide for patients receiving definitive radiotherapy for bladder cancer, particularly for non-cisplatin eligible candidates?

Would you give any adjuvant therapy (chemo, immunotherapy and/or radiation) to a patient with pure small cell cancer of the urinary bladder who received neoadjuvant cisplatin and etoposide but had pN+ and residual invasive disease on cystectomy?

How do you adjust enfortumab vedotin dosing due to side effects?

What is your approach to a patient with muscle invasive bladder cancer getting neoadjuvant gemcitabine/cisplatin who develops significant ototoxicity due to cisplatin after two cycles?

Will you now recommend enfortumab and pembrolizumab for most patients with metastatic urothelial carcinoma, regardless of platinum eligibility, based on the EV 302 presentation at ESMO 2023?

In what situations would you recommend neoadjuvant chemotherapy prior to chemo/RT when pursuing bladder preservation in locally advanced bladder cancer?

Would you recommend "adjuvant" immunotherapy in a older, frail patient who received radiation for upper tract urothelial carcinoma?

Is bilateral hearing loss requiring hearing aids an absolute or relative contraindication for neoadjuvant cisplatin in MIBC?

Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?

Would you consider maintenance immunotherapy after cisplatin-gemcitabine chemotherapy and chemoRT for stage 3 bladder cancer in a patient declining cystectomy or who is a poor surgical candidate?